BioVaxys Technology Corp. (BVAXF)
USD 0.05
(7.06%)
USD 0.05
(7.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.48 Million CAD | 112.65% |
| 2022 | 1.63 Million CAD | 401.46% |
| 2021 | 326.86 Thousand CAD | -63.69% |
| 2020 | 900.09 Thousand CAD | 674.93% |
| 2019 | 116.15 Thousand CAD | -37.1% |
| 2018 | 184.66 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.79 Million CAD | -2.88% |
| 2024 Q1 | 2.87 Million CAD | -17.54% |
| 2024 Q3 | 2.65 Million CAD | -4.82% |
| 2023 Q1 | 1.87 Million CAD | 14.45% |
| 2023 FY | 3.48 Million CAD | 112.65% |
| 2023 Q3 | 2.03 Million CAD | 16.04% |
| 2023 Q4 | 3.48 Million CAD | 71.13% |
| 2023 Q2 | 1.75 Million CAD | -6.43% |
| 2022 Q1 | 868.18 Thousand CAD | 165.61% |
| 2022 Q2 | 1 Million CAD | 16.06% |
| 2022 Q4 | 1.63 Million CAD | -3.02% |
| 2022 FY | 1.63 Million CAD | 401.46% |
| 2022 Q3 | 1.69 Million CAD | 67.74% |
| 2021 Q4 | 326.86 Thousand CAD | 11.84% |
| 2021 Q3 | 292.26 Thousand CAD | -17.8% |
| 2021 Q2 | 355.55 Thousand CAD | 11.49% |
| 2021 Q1 | 318.9 Thousand CAD | -64.57% |
| 2021 FY | 326.86 Thousand CAD | -63.69% |
| 2020 Q1 | 129.85 Thousand CAD | 11.8% |
| 2020 FY | 900.09 Thousand CAD | 674.93% |
| 2020 Q4 | 900.09 Thousand CAD | 21.67% |
| 2020 Q3 | 739.79 Thousand CAD | 328.03% |
| 2020 Q2 | 172.83 Thousand CAD | 33.1% |
| 2019 FY | 116.15 Thousand CAD | -37.1% |
| 2019 Q4 | 116.15 Thousand CAD | 26.83% |
| 2019 Q2 | 95.44 Thousand CAD | 31.96% |
| 2019 Q1 | 72.32 Thousand CAD | 0.0% |
| 2019 Q3 | 91.58 Thousand CAD | -4.04% |
| 2018 FY | 184.66 Thousand CAD | 0.0% |
| 2018 Q3 | 35.13 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.461% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 63.624% |
| SQZ Biotechnologies Company | 50.03 Million USD | 93.034% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 95.19% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 94.094% |
| Mesoblast Limited | 188.44 Million USD | 98.15% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 9.5% |
| Genus plc | 485 Million USD | 99.281% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 40.343% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -38.517% |
| Marizyme, Inc. | 26.67 Million USD | 86.934% |
| ContraFect Corporation | 32.53 Million USD | 89.285% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 8.275% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -75.921% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 8.938% |
| Intellipharmaceutics International Inc. | 12 Million USD | 70.975% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 70.407% |
| MultiCell Technologies, Inc. | 1617.67 USD | -215366.628% |
| Accustem Sciences Inc. | 1.07 Million USD | -222.963% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.498% |
| EV Biologics, Inc. | 2.11 Million USD | -64.796% |
| Q BioMed Inc. | 8.13 Million USD | 57.143% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.797% |
| Neon Bloom, Inc. | 1.22 Million USD | -184.252% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 32.267% |
| Biomind Labs Inc. | 1.49 Million USD | -132.584% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 98.572% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 81.06% |
| Skye Bioscience, Inc. | 14.07 Million USD | 75.231% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -73.399% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2352.964% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 63.178% |
| IMV Inc. | 37.93 Million USD | 90.811% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1633.099% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 39.338% |
| GB Sciences, Inc. | 5.41 Million USD | 35.662% |
| Alpha Cognition Inc. | 7.16 Million USD | 51.352% |
| HST Global, Inc. | 593.59 Thousand USD | -487.193% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Halberd Corporation | 728.71 Thousand USD | -378.31% |
| Enzolytics Inc. | 365.26 Million USD | 99.046% |
| Resverlogix Corp. | 67.39 Million USD | 94.828% |
| Affymax, Inc. | 8.87 Million USD | 60.709% |
| SYBLEU INC | 681.41 Thousand USD | -411.516% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -315.572% |
| argenx SE | 444.95 Million USD | 99.217% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.348% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -103.357% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 70.717% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 4.901% |
| AVAX Technologies, Inc. | 3.99 Million USD | 12.725% |
| Zenith Capital Corp. | 27.56 Thousand USD | -12542.965% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.737% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1360.499% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 6.662% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -411.951% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.064% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 61.453% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5107.816% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -143.088% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 93.066% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -28.54% |
| BioStem Technologies, Inc. | 15.9 Million USD | 78.085% |
| ONE Bio Corp. | 27.49 Million USD | 87.323% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -650.064% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -12605.643% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -176.807% |
| Agentix Corp. | 2.51 Million USD | -38.835% |
| LadRx Corporation | 2.2 Million USD | -58.396% |
| Cell Source, Inc. | 15.8 Million USD | 77.949% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -7698.324% |
| Regen BioPharma, Inc. | 5.45 Million USD | 36.134% |
| Regen BioPharma, Inc. | 5.45 Million USD | 36.134% |
| NovAccess Global Inc. | 7.86 Million USD | 55.659% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 85.915% |
| Itoco Inc. | 1.65 Million USD | -110.842% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -69.897% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 42.378% |
| Kadimastem Ltd | 3.5 Million USD | 0.551% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -726.804% |
| CytoDyn Inc. | 127.89 Million USD | 97.275% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8238.81% |
| Mobile Lads Corp. | 1.31 Million USD | -165.363% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -122.522% |
| Qrons Inc. | 1.48 Million USD | -134.131% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 68.443% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -330.955% |
| Rebus Holdings, Inc. | 5.24 Million USD | 33.507% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 42.878% |
| International Stem Cell Corporation | 5.27 Million USD | 33.948% |
| Bioxytran, Inc. | 3.24 Million USD | -7.264% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -456.965% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 24.508% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 91.498% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 84.345% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -72.092% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 36.372% |
| Neutra Corp. | 973.52 Thousand USD | -258.031% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 87.987% |
| PureTech Health plc | 125.58 Million USD | 97.225% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 7.229% |
| IXICO plc | 1.9 Million USD | -83.421% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 83.021% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.627% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Cellectis S.A. | 249.36 Million USD | 98.602% |